Gastric CancerPhase 4NCT01962376
Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis
A Phase 4 study testing Oxaliplatin;Capecitabine and Oxaliplatin;Capecitabine;Bevacizumab in people with Gastric Cancer and Liver Metastasis, run by Hebei Medical University at 1 site in China.
Trial summary
The investigators assessed whether the addition of a preoperative regimen of Bevacizumab regimen to improves R0 resection rate and survival among patients with potentially resectable gastric cancer with liver metastasis. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Gastric Cancer, Liver Metastasis
- What is being tested?
- Oxaliplatin;Capecitabine and Oxaliplatin;Capecitabine;Bevacizumab
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteChina
- Study dates
- Feb 2013to Apr 2015
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1.Pathological tissue were gastric cancer by gastric and liver biopsy.
- 2.Immunohistochemistry confirmed HER-2 ( - ).
- 3.The number of liver metastasis is less than 3 and evey one is less than 5 cm.
- 4.Liver metastasis must be clinically limited to Type H1 or Type H2.
- 5.gastric cancer were able to resectable lesions or T1-4a N1-2 M0.
- 6.Patients•had not received radiotherapy past and not other organ metastasis and peritoneal metastasis.
Show all 13Show fewer
- 7.Karnofsky performance status performance status >70.
- 8.Inadequate hematopoietic function： Hemoglobin≥90g/L; ANC≥1,500/mm3;Platelet≥100,000/mm3
- 9.Inadequate organ function which is defined as below: Total bilirubin≤1.5 pper limit of normal range (ULN);alanine transaminase / Aspertate aminotransferase≤2.5 upper limit of normal range (ULN) (≤5.0 x ULN if hepatic metastasis); serum creatinine≤1.5 pper limit of normal range (ULN), Serum albumin≥30g/L.
- 10.expectancy must be more than 3 months.
- 11.the random blood or urine pregnancy test in fertile woman must be the negative results in pregnancy test in 7 days.
- 12.Patients for male and female used reliable contraception contraceptive method until the end of study 30 days later.
- Type H1: only one leaf with liver metastasis. Type H2: two leaves with a few scattered metastatic in liver.
Who cannot join
- 1. Patients with other extrahepatic metastasis Include peritoneal metastasis.
- 2. Primary was ulcerative type or the existence of the perforation.
- 3. Patients with other malignancy in 5 years.
- 4. Patients with severe liver disease, kidney disease, respiratory disease , uncontrolled diabetes or severe infections.
- 5.Patients with hypertension failed to control, active bleeding, 3~4 proteinuria, heal the wound, thromboembolisms, heart failure, clinical symptoms of heart disease.
- 6.Patients have obvious peripheral nervous system disorders,mental disorders and disorders of the central nervous system history.
Show all 9Show fewer
- 7.Patients have history of organ transplantation.
- 8.Patients with any medical or psychiatric condition or disease which, in the investigator's judgment, would make the patient inappropriate for entry into this study.
- 9.Patients combined antitumor drug outside the research program.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Department of Internal Medicine-Oncology
Shijiazhuang, Hebei, 050011
Yan Zhang, Doctor, +8613315978336, 13315978336@163.com
Yan Zhang, Doctor
About this study
Official title: Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis
The investigators assessed whether the addition of a preoperative regimen of Bevacizumab regimen to improves R0 resection rate and survival among patients with potentially resectable gastric cancer with liver metastasis.
Read the detailed description
Groups 1:Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis.
Groups 2:Capecitabine Plus Oxaliplatin With placebo in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis.
Group 1 compare with Group 2 in disease-free survival time. Stage I：Preoperative therapy Capecitabine Plus Oxaliplatin With Bevacizumab is superior to Capecitabine Plus Oxaliplatin alines.
Stage II: therapy after surgery Capecitabine Plus Oxaliplatin With Bevacizumab is superior to Capecitabine Plus Oxaliplatin alones after surgery for over 6 months in all.
- Conditions
- Gastric Cancer, Liver Metastasis
- Being tested
- Oxaliplatin;Capecitabine, Oxaliplatin;Capecitabine;Bevacizumab
- Keywords
- Capecitabine, Oxaliplatin, Bevacizumab, Potentially Resectable Gastric Cancer Liver Metastasis
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oxaliplatin;CapecitabineDrug
Also called Oxaliplatin plus capecitabine other names:XELOX.
A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
Oxaliplatin;Capecitabine;BevacizumabDrug
Also called Capecitabine Plus Oxaliplatin Other names XELOX.
A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
| Study group | Role | What they receive |
|---|---|---|
| Bevacizumab,postoperative chemotherapy | Active comparator | Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
placebo:Physiological saline Receives: Drug: Oxaliplatin;Capecitabine; Drug: Oxaliplatin;Capecitabine;Bevacizumab |
| Preoperative Chemotherapy | Experimental | Groups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.placebo:Physiological saline Receives: Drug: Oxaliplatin;Capecitabine; Drug: Oxaliplatin;Capecitabine;Bevacizumab |
What is being measured
The primary outcome is the main question the study is designed to answer.
progression-free survival(PFS)
Measured: 2 years
Secondary outcomes (1)
Objective response rate (ORR)
Measured: within 3 weeks after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Oct 2013 (estimated)
- Study startFeb 2013
- Primary completionDec 2014 (estimated)
- Study completionApr 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hebei Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yan Zhang, Hebei Medical University
- Investigators
- Yan Zhang, Doctor, Principal investigator, Hebei Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01962376
- Sponsor's protocol ID
- YZHANG0001
- Status last verified
- Oct 2013
- First submitted
- 8 Oct 2013
- Last updated
- 14 Oct 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Oct 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis
- ClinicalTrials.gov ID
- NCT01962376
- Acronym / sponsor ID
- YZHANG0001
- Conditions
- Gastric Cancer, Liver Metastasis
- Keywords
- Capecitabine, Oxaliplatin, Bevacizumab, Potentially Resectable Gastric Cancer Liver Metastasis
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Hebei Medical UniversityUniversity, hospital or other
- Study start
- Feb 2013
- Primary completion
- Dec 2014 (estimated)
- Study completion
- Apr 2015 (estimated)
- First posted
- 14 Oct 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators assessed whether the addition of a preoperative regimen of Bevacizumab regimen to improves R0 resection rate and survival among patients with potentially resectable gastric cancer with liver metastasis.
Detailed description
Groups 1:Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis.
Groups 2:Capecitabine Plus Oxaliplatin With placebo in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis.
Group 1 compare with Group 2 in disease-free survival time. Stage I：Preoperative therapy Capecitabine Plus Oxaliplatin With Bevacizumab is superior to Capecitabine Plus Oxaliplatin alines.
Stage II: therapy after surgery Capecitabine Plus Oxaliplatin With Bevacizumab is superior to Capecitabine Plus Oxaliplatin alones after surgery for over 6 months in all.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Bevacizumab,postoperative chemotherapy | Active comparator | Drug: Oxaliplatin;Capecitabine, Drug: Oxaliplatin;Capecitabine;BevacizumabGroups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles. Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles. placebo:Physiological saline |
| Preoperative Chemotherapy | Experimental | Drug: Oxaliplatin;Capecitabine, Drug: Oxaliplatin;Capecitabine;BevacizumabGroups 1 drug: Oxaliplatin;Capecitabine;Bevacizumab A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles. Groups 2 drug: Oxaliplatin;Capecitabine A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.placebo:Physiological saline |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (13 listed)
- 1.Pathological tissue were gastric cancer by gastric and liver biopsy.
- 2.Immunohistochemistry confirmed HER-2 ( - ).
- 3.The number of liver metastasis is less than 3 and evey one is less than 5 cm.
- 4.Liver metastasis must be clinically limited to Type H1 or Type H2.
- 5.gastric cancer were able to resectable lesions or T1-4a N1-2 M0.
Key exclusion criteria (9 listed)
- 1. Patients with other extrahepatic metastasis Include peritoneal metastasis.
- 2. Primary was ulcerative type or the existence of the perforation.
- 3. Patients with other malignancy in 5 years.
- 4. Patients with severe liver disease, kidney disease, respiratory disease , uncontrolled diabetes or severe infections.
- 5.Patients with hypertension failed to control, active bleeding, 3~4 proteinuria, heal the wound, thromboembolisms, heart failure, clinical symptoms of heart disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Oxaliplatin;CapecitabineAlso: Oxaliplatin plus capecitabine other names:XELOX.A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles. | Drug | Bevacizumab,postoperative chemotherapy, Preoperative Chemotherapy |
| Oxaliplatin;Capecitabine;BevacizumabAlso: Capecitabine Plus Oxaliplatin Other names XELOX.A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles. | Drug | Bevacizumab,postoperative chemotherapy, Preoperative Chemotherapy |
Primary outcome
progression-free survival(PFS)
Time frame: 2 years
1 secondary outcome
Objective response rate (ORR)
Time frame: within 3 weeks after surgery
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Oct 2013.
Related trials for Gastric Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yan Zhang, Doctor principal investigator
Hebei Medical University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Oxaliplatin;Capecitabine and Oxaliplatin;Capecitabine;Bevacizumab in people with Gastric Cancer and Liver Metastasis, run by Hebei Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 13 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Oct 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
progression-free survival(PFS) (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2013.